Condition: Cystic Fibrosis in Children · Cystic Fibrosis · Chronic Rhinosinusitis (Diagnosis) · Sponsor: University of California, Los Angeles
This is a prospective, observational study examining the impact of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators on chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) in young children with cystic fibrosis (YCwCF). This study involves two groups: children 2-8 years old, inclusive at initial visit, receiving highly effective modulator therapy (HEMT), and a control group of children 2-8 years old, inclusive at initial visit, not receiving HEMT. Outcomes will include sinus magnetic resonance imaging (MRI) scans, olfactory tests, and quality of life surveys obtained over a two-year period.
This description comes directly from the study's public registry record.
Daniel M Beswick, MD · 310-206-8457 · dbeswick@mednet.ucla.edu
Marlene Florian · 424-946-5862 · mflorian@mednet.ucla.edu
Always discuss trial participation with your own doctor first.
| Children's Hospital Colorado | Aurora, Colorado, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| University of Kansas Medical Center | Kansas City, Kansas, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| University of Vermont | Colchester, Vermont, United States | Recruiting |
| University of Virginia | Charlottesville, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06191640